ZRSR2

Across TCGA pan-cancer cohorts, ZRSR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZRSR2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZRSR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZRSR2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where ZRSR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.441	0.978	<.001	66	view →
LSCC	OS	Median	II,III,IV	0.954	0.772	.001	21	view →
PDAC	DFS	Quartile	All	0.410	0.848	.019	12	view →
CCRCC	OS	Quartile	All	0.739	1.000	.035	6	view →
LUAD	DFS	Tertile	II,III,IV	0.703	0.327	.037	2	view →
UCEC	DFS	Tertile	All	1.000	0.927	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZRSR2–HNSC (DFS)

Open the HNSC breakdown →